Phase 1/2 × Has results × Leukemia, Biphenotypic, Acute × Clear all Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Phase 1/2 Terminated
24 enrolled 15 charts
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Completed
84 enrolled 28 charts
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Phase 1/2 Completed
38 enrolled 12 charts
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
Phase 1/2 Completed
302 enrolled 11 charts
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Phase 1/2 Completed
28 enrolled 13 charts
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 1/2 Completed
199 enrolled 10 charts
Bu Flu TBI
Phase 1/2 Completed
147 enrolled 19 charts
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Completed
74 enrolled 17 charts